Metabotropic glutamate receptor involvement in the pathophysiology of amyotrophic lateral sclerosis: new potential drug targets for therapeutic applications

Research output: Contribution to journalReview article

Abstract

Amyotrophic lateral sclerosis (ALS) is a complex genetic, late age-onset, progressive neurodegenerative disorder leading to the death of upper and lower motor neurons. Life expectancy after diagnosis is short due to the ongoing degeneration and to the lack of effective treatments. Axonal alterations, mitochondrial deficits, RNA changes, protein misfolding and turnover, glial dysfunction and hyperexcitability are key players in molecular mechanisms involved in the degeneration of motor neurons. In the context of hyperexcitability, metabotropic glutamate (mGlu) receptors, which are widely distributed throughout the central nervous system and act through many intracellular signaling pathways, are emerging as novel potential drug targets for the therapeutic treatment of ALS, as they are able to counteract excitotoxicity by reducing glutamate release and inducing the production of neurotrophic factors.

Original languageEnglish
Pages (from-to)65-71
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume38
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Metabotropic Glutamate Receptors
Amyotrophic Lateral Sclerosis
Motor Neurons
Nerve Growth Factors
Life Expectancy
Age of Onset
Neuroglia
Neurodegenerative Diseases
Pharmaceutical Preparations
Glutamic Acid
Central Nervous System
Therapeutics
Proteins
mitochondrial RNA

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

@article{f68a272514fb4d48b14b7a5d86dca23d,
title = "Metabotropic glutamate receptor involvement in the pathophysiology of amyotrophic lateral sclerosis: new potential drug targets for therapeutic applications",
abstract = "Amyotrophic lateral sclerosis (ALS) is a complex genetic, late age-onset, progressive neurodegenerative disorder leading to the death of upper and lower motor neurons. Life expectancy after diagnosis is short due to the ongoing degeneration and to the lack of effective treatments. Axonal alterations, mitochondrial deficits, RNA changes, protein misfolding and turnover, glial dysfunction and hyperexcitability are key players in molecular mechanisms involved in the degeneration of motor neurons. In the context of hyperexcitability, metabotropic glutamate (mGlu) receptors, which are widely distributed throughout the central nervous system and act through many intracellular signaling pathways, are emerging as novel potential drug targets for the therapeutic treatment of ALS, as they are able to counteract excitotoxicity by reducing glutamate release and inducing the production of neurotrophic factors.",
author = "Giuseppe Battaglia and Valeria Bruno",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.coph.2018.02.007",
language = "English",
volume = "38",
pages = "65--71",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Metabotropic glutamate receptor involvement in the pathophysiology of amyotrophic lateral sclerosis

T2 - new potential drug targets for therapeutic applications

AU - Battaglia, Giuseppe

AU - Bruno, Valeria

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Amyotrophic lateral sclerosis (ALS) is a complex genetic, late age-onset, progressive neurodegenerative disorder leading to the death of upper and lower motor neurons. Life expectancy after diagnosis is short due to the ongoing degeneration and to the lack of effective treatments. Axonal alterations, mitochondrial deficits, RNA changes, protein misfolding and turnover, glial dysfunction and hyperexcitability are key players in molecular mechanisms involved in the degeneration of motor neurons. In the context of hyperexcitability, metabotropic glutamate (mGlu) receptors, which are widely distributed throughout the central nervous system and act through many intracellular signaling pathways, are emerging as novel potential drug targets for the therapeutic treatment of ALS, as they are able to counteract excitotoxicity by reducing glutamate release and inducing the production of neurotrophic factors.

AB - Amyotrophic lateral sclerosis (ALS) is a complex genetic, late age-onset, progressive neurodegenerative disorder leading to the death of upper and lower motor neurons. Life expectancy after diagnosis is short due to the ongoing degeneration and to the lack of effective treatments. Axonal alterations, mitochondrial deficits, RNA changes, protein misfolding and turnover, glial dysfunction and hyperexcitability are key players in molecular mechanisms involved in the degeneration of motor neurons. In the context of hyperexcitability, metabotropic glutamate (mGlu) receptors, which are widely distributed throughout the central nervous system and act through many intracellular signaling pathways, are emerging as novel potential drug targets for the therapeutic treatment of ALS, as they are able to counteract excitotoxicity by reducing glutamate release and inducing the production of neurotrophic factors.

UR - http://www.scopus.com/inward/record.url?scp=85043393884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043393884&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2018.02.007

DO - 10.1016/j.coph.2018.02.007

M3 - Review article

AN - SCOPUS:85043393884

VL - 38

SP - 65

EP - 71

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -